FCMI
SIOX

Foresite Capital Management II’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Foresite Capital Management II’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-8,125
Closed -$1.17M – 21
2015
Q4 		$1.17M Hold
8,125
– – 0.39% 22
2015
Q3 		$840K Hold
8,125
– – 0.26% 28
2015
Q2 		$1.32M Buy
+8,125
New +$1.38M 0.47% 18

Other funds holding SIOX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Foresite Capital Management II's SIOX Position: Q1 2016 in Review

Foresite Capital Management II sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2016, closing a stake of 8,125 shares — an estimated $1.17M sold.

Foresite Capital Management II first reported a position in SIOX in Q2 2015 and held it in 3 quarters. The position peaked at $1.32M in Q2 2015. 70 funds tracked by Wall St. Rank hold SIOX as of Q1 2016.

  • Foresite Capital Management II reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Foresite Capital Management II sold 8,125 Sio Gene Therapies Inc. Common Stock shares in Q1 2016, an estimated $1.17M.
  • Foresite Capital Management II first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 3 quarters.
  • Foresite Capital Management II's Sio Gene Therapies Inc. Common Stock position peaked at $1.32M in Q2 2015.
  • 70 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2016.

Based on Foresite Capital Management II's 13F filing for Q1 2016, filed 6 May 2016.